Literature DB >> 16426017

Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses.

Filippo Ansaldi1, Sabrina Bacilieri, Federica Banfi, Paolo Durando, Laura Sticchi, Giancarlo Icardi, Roberto Gasparini.   

Abstract

Evaluation of the antibody responses induced by the 2004-2005 influenza vaccine strain against the homologous variant, the 2004-2005 field isolates, and a previous circulating strain showed that a correlation between neutralizing and hemagglutination-inhibiting activities exists only when the antigen is very close to the vaccine strain.

Mesh：

Substances：

Year:  2006        PMID： 16426017      PMCID： PMC1356628          DOI： 10.1128/CVI.13.1.162-164.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  15 in total

1.  Overcoming original (antigenic) sin.

Authors:  D E Anderson; M P Carlos; L Nguyen; J V Torres
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

2.  Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season.

Authors:  Filippo Ansaldi; Pierlanfranco D'Agaro; Daniela De Florentiis; Simona Puzelli; Yi Pu Lin; Victoria Gregory; Michael Bennett; Isabella Donatelli; Roberto Gasparini; Pietro Crovari; Alan Hay; Cesare Campello
Journal:  J Med Virol       Date:  2003-07       Impact factor: 2.327

3.  Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine--Colorado, December 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-01-16       Impact factor: 17.586

4.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

Authors:  W E P Beyer; A M Palache; G Lüchters; J Nauta; A D M E Osterhaus
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

5.  New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season.

Authors:  Filippo Ansaldi; Giancarlo Icardi; Roberto Gasparini; Cesare Campello; Simona Puzelli; Antonino Bella; Isabella Donatelli; Stefania Salmaso; Pietro Crovari
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection.

Authors:  M W Harmon; P A Rota; H H Walls; A P Kendal
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

7.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus.

Authors:  H Kida; L E Brown; R G Webster
Journal:  Virology       Date:  1982-10-15       Impact factor: 3.616

8.  Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Daniela Amicizia; Laura Valle; Federica Banfi; Paolo Durando; Laura Sticchi; Roberto Gasparini; Giancarlo Icardi; Pietro Crovari
Journal:  J Med Virol       Date:  2004-09       Impact factor: 2.327

9.  Recommended composition of influenza virus vaccines for use in the 2004 influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2003-10-24

10.  Influenza A (H3N2) outbreak, Nepal.

Authors:  Luke T Daum; Michael W Shaw; Alexander I Klimov; Linda C Canas; Elizabeth A Macias; Debra Niemeyer; James P Chambers; Robert Renthal; Sanjaya K Shrestha; Ramesh P Acharya; Shankar P Huzdar; Nirmal Rimal; Khin S Myint; Philip Gould
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883
View more
  3 in total

Review 1.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

2.  Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Michele Pellegrini; Gabriele Angiolelli; Silvia Majori; Annarosa Floreani; Marta Cecilia Busana; Chiara Bertoncello; Renzo Trivello
Journal:  Clin Dev Immunol       Date:  2010-03-29

Review 3.  MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Authors:  Angelika Banzhoff; Michele Pellegrini; Giuseppe Del Giudice; Elena Fragapane; Nicola Groth; Audino Podda
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.